Compare Garmin Ltd. (GRMN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs State Street SPDR S&P Biotech ETF — how do they compare? Garmin Ltd. trades at $306.5 (market cap $59.72B), while State Street SPDR S&P Biotech ETF trades at $158.91. The key difference: Garmin Ltd. pays a 1.36% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| GRMN | XBI | |
|---|---|---|
Market Cap | $59.72B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $313.16 | $164.28 |
52-Week Low | $187.10 | $86.92 |
Enterprise Value | $57.23B | — |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $313.16, up 0.73% on the day and near its all-time high, with a bullish technical trend and strong support at $309. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.81 beating estimates of $2.30, and raised full-year guidance. Revenue growth accelerated to 11% in Q2 2026, driven by strong performance in the fitness segment, while net income margin improved to 24.47%.
The outlook remains positive given robust fundamentals and raised guidance, but risks include rich valuation multiples, potential growth deceleration, and insider selling. Analyst consensus is cautious with a hold-heavy rating, though the average price target of $318.67 suggests modest upside from current levels.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
